Member Exclusive News

Therapeutic for Alzheimer's disease shows improved safety profile

​In a direct comparison, ProMIS Neurosciences’ oligomer-selective antibody (PMN310) reveals a potential advantage over other antibody therapeutics for Alzheimer's disease.​

Go to the profile of Jasmine Harris
Aug 28, 2018
0
0

Please sign in or register for FREE

Register to MedChemNet

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

No comments yet.